Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Non-Current Assets data on file, last reported at $17.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 19.02% year-over-year to $17.2 million in Q1 2026; TTM through Mar 2026 was $75.2 million, a 47.59% decrease from a year earlier, with the FY2025 full-year figure at $18.3 million, down 12.77% from the prior year.
• Non-Current Assets for Q1 2026 stood at $17.2 million, down from $18.3 million in the prior quarter.
• Over the last five years, Non-Current Assets for ARTV reached as high as $75.0 million in Q3 2024 and fell as low as $17.2 million in Q1 2026.
• Historically, Non-Current Assets has averaged $27.1 million across 4 years, with a median of $21.0 million in 2024.
• On a YoY basis, Non-Current Assets climbed as much as 12.77% in 2025 and fell as far as 74.23% in 2025.
• Year by year, Non-Current Assets stood at $25.3 million in 2023, then dropped by 17.17% to $21.0 million in 2024, then dropped by 12.77% to $18.3 million in 2025, then fell by 5.8% to $17.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $17.2 million in Q1 2026, $18.3 million in Q4 2025, and $19.3 million in Q3 2025.